Status and phase
Conditions
Treatments
About
The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Concurrent use of non-insulin therapies aimed to control hyperglycemia or use within the past 30 days of screening MMTT (V-2).
History of severe reaction or anaphylaxis to human, humanized or murine monoclonal antibodies.
Diagnosis of liver disease or elevated hepatic enzymes, as defined by ALT or AST> 1.5 x the upper limit of age-determined normal (ULN) .
Females who are pregnant or lactating.
Receipt of an immune modulating biologic or investigational drug within 3 months or 5 half-lives before enrollment.
History of other clinically significant autoimmune disease needing chronic therapy with biologics or steroids with the exception of celiac and stable thyroid disease.
Current use of any medication known to significantly influence glucose tolerance (e.g. oral steroids, atypical antipsychotics, diphenylhydantoin, niacin).
Any medical or psychological condition that in the opinion of the principal investigator would interfere with the safe completion of the trial.
For Study A (liraglutide)
For Study B (golimumab)
Any history of recent (within 3 months) serious bacterial, viral, fungal, or other opportunistic infections.
Any history of demyelinating diseases (such as multiple sclerosis), heart failure, or left ventricular dysfunction.
Serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C.
Positive QuantiFERON or PPD TB test, history of tuberculosis, or active TB infection.
Active infection with EBV, defined by real-time PCR.
Active infection with CMV, defined by real-time PCR.
Any of the following hematologic abnormalities at screening:
Receipt of live vaccine (in the 6 weeks before treatment)
Primary purpose
Allocation
Interventional model
Masking
16 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal